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Necroptosis, a form of regulated necrotic cell death, is governed by
RIP1/RIP3-mediated activation of MLKL. However, the signaling
process leading to necroptotic death remains to be elucidated. In
this study, we found that PUMA, a proapoptotic BH3-only Bcl-2
family member, is transcriptionally activated in an RIP3/MLKL-
dependent manner following induction of necroptosis. The induc-
tion of PUMA, which is mediated by autocrine TNF-α and enhanced
NF-κB activity, contributes to necroptotic death in RIP3-expressing
cells with caspases inhibited. On induction, PUMA promotes the
cytosolic release of mitochondrial DNA and activation of the DNA
sensors DAI/Zbp1 and STING, leading to enhanced RIP3 and MLKL
phosphorylation in a positive feedback loop. Furthermore, dele-
tion of PUMA partially rescues necroptosis-mediated developmen-
tal defects in FADD-deficient embryos. Collectively, our results
reveal a signal amplification mechanism mediated by PUMA and
cytosolic DNA sensors that is involved in TNF-driven necroptotic
death in vitro and in vivo.
PUMA | necroptosis | RIP3 | MLKL | NF-κB
Necroptosis has recently emerged as a critical regulated formof necrotic cell death in physiology and human diseases (1–
4). Necroptosis can be triggered by various extracellular stimuli
known to activate inflammation and cell death. Distinctive from
apoptosis, necroptosis is morphologically characterized by early
loss of plasma membrane integrity, leakage of intracellular con-
tents, and organelle swelling (1). Induction of necroptosis is con-
trolled by two essential serine-threonine kinases, RIP1 and RIP3
(5, 6). On induction of necroptosis, RIP1 and RIP3 form a func-
tional amyloid signaling complex (7) that recruits mixed-lineage
kinase domain-like protein (MLKL) to initiate the process of cell
death (8). Although RIP1/RIP3-mediated signaling has been ex-
tensively studied, the effectors and molecular events in the signal
amplification and execution of necroptosis remain unclear (9).
Bcl-2 family proteins are evolutionarily conserved cell death
regulators that include prosurvival members, such as Bcl-2 and
Bcl-XL, and the proapoptotic members Bax/Bak and BH3-only
proteins (10). In apoptosis, these proteins control mitochondrial
outer membrane permeabilization (MOMP), which leads to
caspase activation and execution of cell death. PUMA is a BH3-
only Bcl-2 family protein that mediates the apoptotic response to
a variety of stress conditions, including DNA damage, oncogene
activation, inflammation, and viral infection (11). In response to
these conditions, PUMA is transcriptionally activated by p53,
Forkhead Box O3a (FOXO3a), p73, c-Myc, E2F1, or NF-κB
(11). It binds to prosurvival Bcl-2 proteins to activate Bax and
Bak and promote MOMP and caspase activation. Several studies
have suggested that Bcl-2 family proteins are also involved in
regulating necroptosis (12, 13); however, their role in non-
apoptotic death is not well understood.
Our previous studies showed that PUMA can be induced by
NF-κB in response to inflammation and TNF-α (14, 15), which
can trigger necroptosis in cells in which caspases are inhibited
(5). Thus, we investigated a potential role of PUMA in nec-
roptosis. Our results demonstrate that PUMA is activated in a
RIP3/MLKL-dependent manner and promotes signal amplifi-
cation in TNF-driven necroptosis in vitro and in vivo in a positive
feedback loop.
Results
PUMA Is Transcriptionally Activated During RIP1/RIP3-Dependent
Necroptosis. RIP1/RIP3-dependent necroptosis can be induced
in HT29 colon cancer cells in response to inhibitor of apoptosis
protein (IAP) inhibition by SMAC mimetics and caspase in-
hibition by caspase inhibitors (5). We treated HT29 cells with the
SMAC mimetic LBW-242 (L) and the pan-caspase inhibitor
z-VAD-fmk (z-VAD; Z) to induce necroptosis. Induction of nec-
roptosis was analyzed by several methods (Fig. 1A), including
loss of cell viability by crystal violet staining (5), depletion of
intracellular ATP (5), propidium iodide (PI) staining for non-
apoptotic death, extracellular release of nuclear High-Mobility
Group Box 1 (HMGB1) (16), and inhibition of cell death by the
RIP1 inhibitor necrostatin-1 (Nec-1; N) (17). Analysis of Bcl-
2 family proteins revealed a marked induction of PUMA in
HT29 cells after treatment with L+Z, but not after treatment
with either compound alone (Fig. 1A). Both PUMA protein and
mRNA were induced in a time-dependent fashion following
L+Z treatment (Fig. 1B). In addition to PUMA, Bcl-XL was also
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induced, while other Bcl-2 family members, including Bcl-2,
Mcl-1, Bax, Bid, Bim, and Bad, were not significantly changed
(Fig. S1 A and B). PUMA induction was detected in mouse
embryonic fibroblast (MEF) cells undergoing necroptosis in-
duced by TNF-α, LBW-242, and z-VAD (T+L+Z) (Fig. 1C)
(18). The time course and extent of PUMA induction were found
to correlate with HMGB1 release in both HT29 cells and MEFs
(Fig. 1B and Fig. S1C).
The treatment with RIP1 inhibitor Nec-1 abolished PUMA
induction in both HT29 cells and MEFs undergoing necroptosis,
coinciding with restoration of cell viability and suppression of
HMGB1 release (Fig. 1 A and C). Knockdown of RIP1 or RIP3
by shRNA suppressed induction of PUMA and necroptosis by
L+Z in HT29 cells (Fig. 1D and Fig. S1D). PUMA induction was
detectable at 1–2 h after RIP3 S227 phosphorylation (Fig. 1E),
an early event in necroptosis signaling (4). While RIP1 is ubiq-
uitously expressed, RIP3 is often epigenetically silenced in can-
cer cell lines (19), and its expression determines whether cells
can undergo necroptosis (5). Our analysis of 16 cell lines iden-
tified several colon cancer cell lines that express RIP3 in addition
to HT29 (Fig. S1E). Induction of PUMA and necroptosis was
observed in RIP3-expressing LoVo and SW1463 cells following
L+Z treatment and blunted by Nec-1 (Fig. S1F), but not in HCT116
and RKO cells lacking RIP3 (Fig. S1G). RIP1-dependent in-
duction of PUMA and Bcl-XL was also found in necroptosis
induced by TNF-α and LBW-242 (T+L) in FADD null Jurkat
cells (Fig. S1H). These results indicate that PUMA is transcrip-
tionally activated during RIP1/RIP3-dependent necroptosis in
different cell types.
PUMA Induction Requires MLKL and Is Mediated by Autocrine TNF-α
and Enhanced NF-κB Activity. We investigated the mechanism of
PUMA induction during necroptosis. Execution of necroptosis is
characterized by formation of the necrosome complex and acti-
vation of MLKL through its phosphorylation (8). PUMA in-
duction by L+Z in HT29 cells was detectable shortly after the
onset of RIP3-dependent MLKL phosphorylation (Fig. 1E and
Fig. S1I) and was suppressed by MLKL knockdown (Fig. 2A and
Fig. S1J) or the MLKL inhibitor necrosulfonamide (NSA; Fig.
2B) (8). PUMA induction in necroptosis is unrelated to p53,
STAT1, p73, FOXO3a, or E2F1 (Fig. S2 A–C). We previously
showed that PUMA can be induced by the p65 subunit of NF-κB
in response to TNF-α (15). Knockdown of p65 suppressed
PUMA induction and necroptosis in HT29 and SW1463 cells
treated with L+Z (Fig. 2C and Fig. S2D). p65 knockout (KO) in
MEFs also abrogated PUMA induction, but did not inhibit cell
death induced by T+L+Z (Fig. S2E). Treating HT29 cells with
L+Z induced p65 nuclear translocation (Fig. S2F), p65 binding
to the PUMA promoter (Fig. 2D), and activation of a PUMA
promoter reporter via an NF-κB binding site (Fig. S2G) (15).
It has been shown that NF-κB can be activated by RIP1 in
necroptosis signaling (20). We detected two phases of NF-κB
activation by p65 phosphorylation (S536) (Fig. 2E). The first
phase occurred at 3–12 h and was RIP1-dependent (Fig. S2H),
but it did not correlate with MLKL phosphorylation or PUMA
induction after 12 h (Fig. 2E) and was not affected by MLKL
knockdown or inhibition (Fig. 2 A and B). The second phase of
p65 phosphorylation after 12 h was MLKL-dependent (Fig. 2 A
and B) and consistent with MLKL phosphorylation and PUMA
induction (Fig. 2E). The enhanced NF-κB activity and PUMA
induction were due to autocrine TNF-α, as TNF-α mRNA and
secretion were markedly increased at 12–18 h and were sup-
pressed by MLKL knockdown or inhibition (Fig. 2F and Fig.
S2I). Extracellular addition of the anti-TNF antibody infliximab
(Remicade) abolished the enhanced p65 phosphorylation and
PUMA induction, as well as necroptosis, in HT29 cells treated
with L+Z (Fig. S2J). Furthermore, activation of the PUMA
promoter by L+Z could be suppressed by inhibition of TNF,
RIP1, MLKL, or NF-κB (Fig. S2G). These results indicate that
PUMA is directly activated by NF-κB via autocrine TNF-α at the
early execution stage of necroptosis following MLKL activation.
PUMA Contributes to Necroptosis in RIP3-Expressing Cells with Caspase
Inhibition. We asked whether PUMA plays a functional role in
necroptotic death. Knockdown of PUMA by shRNA or siRNA
largely suppressed cell viability loss, ATP depletion, PI staining,
and HMGB1 release in HT29, LoVo, and SW1463 cells treated
with necroptotic stimuli (Fig. 3A and Fig. S3A). HT29 cells
with PUMA KO by CRISPR/Cas9 showed similar phenotypes
as PUMA-knockdown cells (Fig. S3B). TEM analysis showed
PUMA-knockdown cells lacked morphological signs of necroptosis
observed in the control cells, including plasma membrane per-
meabilization, translucent cytosol, and swollen mitochondria (1)
(Fig. 3B). Interestingly, PUMA depletion suppressed the en-
hanced RIP3 and MLKL phosphorylation after onset at 12–14 h
following L+Z treatment (Fig. 3 A and C), suggesting that PUMA
induction provides positive feedback to RIP3 and MLKL to am-
plify the necroptosis signal.
Fig. 1. PUMA is induced in RIP1/RIP3-dependent necroptosis. (A) HT29 colon
cancer cells were treated with the control DMSO (Un), LBW242 (L; 2 μM),
z-VAD (Z; 10 μM), Necrostatin-1 (N; 20 μM), or the indicated combinations.
(Upper) Crystal violet staining at 48 h. (Middle) ATP levels and PI staining at
48 h. (Lower) Western blots of PUMA in cell lysates and HMGB1 in 20 μL of
cell culture medium at 24 h. (B) HT29 cells were treated with LBW242 and
z-VAD (L+Z) as in A. (Upper) PUMA expression and HMGB1 release. (Lower)
PUMA mRNA expression. (C) MEFs were treated with LBW242 (L; 2 μM),
alone or in combination with TNF-α (T; 20 ng/mL), z-VAD (Z; 10 μM), or
Necrostatin-1 (N; 20 μM). ATP levels and PI staining (Upper) and PUMA ex-
pression and HMGB1 release (Lower) were analyzed as in A. (D) HT29 cells
stably expressing control or RIP3 shRNA were treated and analyzed as in A.
(E) Western blots of phospho-RIP3 (p-RIP3; S227), phospho-MLKL (p-MLKL;
S358), and PUMA in HT29 cells treated with L+Z at the indicated time points.
Values in A–D are expressed as mean ± SD. n = 3. **P < 0.01.
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The pan-kinase inhibitor staurosporine (STS), a widely used
apoptosis inducer, can induce necroptosis under certain condi-
tions (21). PUMA can be induced by STS and contributes to
STS-induced apoptosis (22). PUMA depletion suppressed STS-
induced and RIP3/MLKL-dependent necroptosis in RIP3-expressing
HT29 and LoVo cells with caspase inhibition (Fig. S3 C–F), but
not in HCT116 cells lacking RIP3 (Fig. S3G). PUMA induction
also contributed to the necroptosis induced by T+L in FADD
null Jurkat cells (Fig. S3H). PUMA KO in MEFs suppressed the
necroptosis induced by T+L+Z (Fig. 3D) or enforced RIP3 di-
merization (23) (Fig. S4 A and B). Furthermore, PUMA KO
modestly reduced the necroptosis induced by relatively high
doses of TNF-α and z-VAD (T+Z) (24), but had little or no
effect on that induced by bacterial lipopolysaccharides (LPS)
or Poly I:C in MEFs and bone marrow-derived macrophages
(BMDMs) (Fig. S4 C and D), which could be blocked by RIP3 or
MLKL KO (24).
We then tested whether PUMA induction alone is sufficient
to induce necroptosis. Infection of HT29 and HCT116 cells
with PUMA-expressing adenovirus (Ad-PUMA), but not with
adenovirus expressing BH3-deleted PUMA, induced apoptosis
detected by nuclear fragmentation and caspase activation (Fig.
4 A and B and Fig. S5). Caspase inhibition by z-VAD in con-
junction with Ad-PUMA infection changed the mode of death
in HT29 cells from apoptosis to necroptosis, as demonstrated
by blockage of nuclear fragmentation and caspase 3 cleavage but
increases in HMGB1 release, PI staining, and RIP3 and MLKL
phosphorylation (Fig. 4A). Plasma membrane permeabilization,
translucent cytosol, and swollen mitochondria were detected
in HT29 cells undergoing necroptosis induced by Ad-PUMA +
z-VAD (Fig. 4B). Knockdown of RIP3 or MLKL suppressed the
necroptotic death induced by Ad-PUMA + z-VAD (Fig. 4 C
and D). In contrast, z-VAD treatment completely blocked the
PUMA-induced death of HCT116 cells, without HMGB1 release
or morphological signs of necroptosis (Fig. S5). These results
demonstrate that PUMA by itself can promote RIP3/MLKL-
dependent necroptosis in RIP3-expressing cells with caspase
inhibition.
PUMA Provides Positive Feedback to RIP3/MLKL by Promoting Cytosolic
Release of Mitochondrial DNA and Activation of DNA Sensors. The
requirement for its BH3 domain (Fig. 4A) suggests that PUMA
mediates necroptosis through its interactions with other Bcl-2
Fig. 2. Induction of PUMA is mediated by NF-κB downstream of MLKL. (A) HT29 cells transfected with control scrambled orMLKL siRNA were treated with L+Z.
(Upper) ATP levels at 48 h. (Lower) Protein expression and HMGB1 release at 24 h. (B) HT29 cells with or without pretreatment with NSA (1 μM) were treated and
analyzed as in A. (C) HT29 cells transfected with control scrambled or p65 siRNA were treated with L+Z as in A. ATP levels at 24 h (Upper), indicated proteins at
48 h (Middle), and PUMAmRNA expression at 24 h (Lower) were analyzed. (D) Chromatin immunoprecipitation (ChIP) analysis of the binding of p65 to the PUMA
promoter in HT29 cells treated as in A for 24 h. (E) Western blots of total and phospho-p65 (p-p65; S536) at indicated time points in HT29 cells treated as in
A. (F) TNF-α secretion at indicated time points in HT29 cells treated as in A. Values in A–C and F are expressed as mean ± SD. n = 3. *P < 0.05.
Fig. 3. PUMA induction contributes to necroptosis and enhanced RIP3
and MLKL phosphorylation in RIP3-expressing cells with caspase inhibition.
(A) HT29 cells expressing control, PUMA, or RIP3 shRNA were treated with
L+Z. (Upper) Crystal violet staining at 48 h. (Middle) ATP levels at 48 h. (Lower)
Western blots of indicated proteins and HMGB1 release at 24 h. (B) Repre-
sentative TEM pictures of HT29 cells treated as in A for 24 h. Black arrowheads
indicate mitochondria, and white arrowheads indicate plasma membranes.
(Scale bars: 2 μm.) (C) Western blots of indicated proteins in HT29 cells
transfected with control or PUMA shRNA treated with L+Z. (D) WT and
PUMA KOMEFs were treated with 20 ng/mL TNF-α, 2 μM LBW242, and 10 μM
z-VAD (T+L+Z) and analyzed as in A. Values in A and D are expressed as
mean ± SD. n = 3. NS, P > 0.05; *P < 0.05; **P < 0.01.
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family proteins, such as Bcl-XL, which was induced by L+Z (Fig. S1
A, B, and H). Bcl-XL transfection suppressed necroptosis in HT29
cells (Fig. S6A), whereas its knockdown enhanced necroptosis and
abrogated the effect of PUMA knockdown (Fig. S6 B and C),
suggesting that PUMA promotes necroptosis by antagonizing
Bcl-XL. However, knockdown of BAX and BAK in HT29 cells
did not affect necroptosis and RIP3/MLKL phosphorylation in-
duced by Ad-PUMA + z-VAD (Fig. S6D). BAX/BAK double-KO
(DKO) MEFs had intact necroptosis, PUMA induction, and MLKL
phosphorylation in response to T+L+Z (Fig. S6E); therefore, Bax/
Bak-mediated MOMP, a key feature of apoptosis, is not involved
in PUMA-mediated necroptosis.
Interestingly, we detected cytosolic release of mitochondrial
DNA in both HT29 cells and MEFs undergoing necroptosis, as
indicated by enhanced cytosolic DNA staining (green), as well as
reduced colocalization (yellow) of mitochondria (red) and DNA,
which is correlated with reduced mitochondrial interconnectivity
and elongation (Fig. 5A and Fig. S6F). Genomic PCR analysis
confirmed the release of mitochondrial cytochrome B (CytB)
DNA into the cytosol of necroptotic HT29 cells and MEFs (Fig.
5B and Fig. S6G). The release of mitochondrial DNA was de-
pendent on PUMA and was suppressed in PUMA-depleted
HT29 and PUMA KO MEFs (Fig. 5 A and B and Fig. S6 F and
G). Depleting mitochondrial DNA by ethidium bromide (EB)
treatment suppressed the necroptosis induced by L+Z in HT29
cells (Fig. S7 A and B).
Exogenous viral DNA and endogenous self-DNA in the cytosol
can trigger activation of DNA sensors, such as DAI/Zbp1 and
cGAS/STING (25), which are involved in necroptosis (26, 27).
Our analysis of several DNA sensors detected induction of DAI/
Zbp1 mRNA and protein in HT29 cells and MEFs undergoing
necroptosis, as well as depletion of STING (Fig. 5C and Fig. S7C),
which is known to be rapidly degraded following cGAS-mediated
activation in response to cytosolic DNA (28). These changes in
DNA sensors were abrogated in PUMA-deficient HT29 cells and
MEFs (Fig. 5C and Fig. S7 D and E). Treatment of HT29 cells
with Ad-PUMA + z-VAD also induced DAI/Zbp1 expression and
STING degradation (Fig. 5D). Enhanced binding of DAI/Zbp1 to
Fig. 4. PUMA expression alone can induce necroptosis and RIP3 and MLKL
phosphorylation in RIP3-expressing cells with caspase inhibition. (A) HT29 cells
with or without pretreatment with 10 μM z-VAD were infected with control
(BH3 domain deleted; ΔBH3) or PUMA-expressing adenovirus (Ad-PUMA).
(Upper) Crystal violet staining at 24 h. (Middle) analysis of apoptosis and PI
staining at 48 h. (Lower) Western blots of indicated proteins and HMGB1 release
at 24 h. (B) Representative TEM pictures of HT29 cells treated as in A for 24 h.
Black arrowheads indicate mitochondria, and white arrowheads indicate plasma
membranes. (Scale bars: 2 μm.) (C) HT29 cells stably transfected with control or
RIP3 shRNA were treated and analyzed as in A. (D) HT29 cells transfected with
control scrambled or MLKL siRNA were treated and analyzed as in A. Values in
A, C, and D are expressed as mean ± SD. n = 3. *P < 0.05; **P < 0.01.
Fig. 5. PUMA promotes mitochondrial DNA release and activates DNA sensors to enhance RIP3/MLKL activation in necroptosis. (A) HT29 cells stably
expressing control or PUMA shRNA were treated with L+Z for 24 h. Cells were analyzed by confocal microscopy after mitochondria staining with MitoTracker
(red) and DNA staining with PicoGreen (green). (Left) Representative pictures with the arrow indicating cytoplasmic DNA. (Scale bars: 5 μm.) (Right)
Quantification of colocalization of MitoTracker and PicoGreen staining and mitochondrial interconnectivity and elongation by Image J software in at least
20 randomly selected individual cells. (B) Mitochondrial and cytosolic fractions isolated from an equal number of HT29 cells treated as in A were analyzed by
genomic PCR for CytB. (C) Western blots of DAI/Zbp1 and STING in HT29 cells treated as in A. (D) Western blots of DAI/Zbp1 and STING in HT29 cells infected
with control (Ad-ΔBH3) or PUMA-expressing adenovirus (Ad-PUMA) and treated with 10 μM z-VAD for 24 h. (E) HT29 cells transfected with GFP-tagged full-
length DAI/Zbp1 (WT) or a deletion mutant of its N-terminal DNA binding domain (mutant) were treated with L+Z as in A. Transfected DAI/Zbp1 was ex-
amined by Western blot analysis (Lower) and pulled down by IP with anti-GFP antibody, followed by PCR analysis of mitochondrial CytB and ND2 DNA.
(F) HT29 cells stably expressing control or DAI/Zbp1 shRNA were transfected with control scrambled or STING siRNA and then treated as in A. (Upper) ATP
levels at 48 h. (Lower) Western blots of indicated proteins and HMGB1 release at 24 h. Values in F are expressed as mean ± SD. n = 3. *P < 0.05; **P < 0.01.
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mitochondrial CytB and NADH dehydrogenase 2 (ND2) genomic
DNA, which requires the DNA-binding domain of DAI/Zbp1, was
detected by immunoprecipitation in HT29 cells treated with L+Z
(Fig. 5E). Knockdown of both DAI/Zbp1 and STING abrogated
necroptosis and RIP3/MLKL phosphorylation in HT29 cells,
which was less affected by knockdown of either gene (Fig. 5F).
Furthermore, IFN-α and -β were induced in necroptotic HT29
cells, which was suppressed by depletion of RIP3, PUMA, DAI/
Zbp1, or STING (Fig. S7 F and G). Knockdown of IFN-α/β re-
ceptor 1 (IFNAR1) reduced necroptosis in HT29 cells (Fig. S7 H
and I). These results suggest that on activation by RIP3/MLKL,
PUMA promotes mitochondrial DNA release and activation of
DNA sensors, which cooperate to promote IFN response and en-
hanced RIP3/MLKL phosphorylation in a positive feedback loop.
PUMA KO Delays the Embryonic Lethality Caused by FADD KO. The
physiological role of RIP1/RIP3-mediated necroptosis has been
demonstrated by mouse genetic studies in which RIP1 or RIP3
deficiency rescues developmental defects and/or embryonic
death caused by deficiency in caspase 8 or FADD (29–31). To
investigate the role of PUMA in necroptosis in vivo, we de-
termined whether PUMA KO can also rescue the developmental
defects in FADD KO mice (31). Genotyping of 102 newborn
mice from the breeding of PUMA heterozygous (PUMA+/−) and
FADD heterozygous (FADD+/−) mice did not identify any with
the FADD−/− genotype, indicating that PUMA KO cannot rescue
the postnatal lethality of FADD KO mice (31). Thus, we per-
formed embryo dissection at several time points after pregnancy.
Among 185 embryos dissected at E13.5, we identified 11 with the
FADD−/−/PUMA−/− DKO genotype (Fig. 6 A and B and Fig.
S8A). This frequency (11 of 185) matched that of the Mendelian
inheritance of PUMA KO and FADD KO alleles (Fig. 6C) and
was statistically significant (P < 0.001, DKO vs. FADD KO). In
contrast, only one (of 12 expected) FADD−/−/PUMA+/+ embryo
and five FADD−/−/PUMA+/− embryos (of 23 expected) were found
(Fig. 6 A–C and Fig. S8A), suggesting a gene dosage effect of the
PUMA KO allele. Despite being slightly smaller, the DKO em-
bryos at embryonic day (E) 13.5 appeared to be grossly normal
compared with WT embryos (Fig. 6A). Dissection at E11.5 re-
covered abnormally developed FADD KO embryos among com-
pletely normal-looking DKO embryos (Fig. S8B). H&E staining of
embryonic tissues revealed massive cell loss in FADD−/−/PUMA+/−
embryos at E13.5, which was absent in the DKO embryos (Fig.
S8C). In contrast to WT and DKO embryos with nuclear HMGB1,
FADD KO embryos exhibited cytoplasmic HMGB1, suggestive
of its release and necrotic death (Fig. 6D), which was also in-
dicated by positive TUNEL staining but negative active caspase
3 staining (Fig. S8 D and E). Furthermore, DKO embryos
exhibited reduced MLKL phosphorylation, DAI/Zbp1 induction,
and STING depletion compared with FADD KO embryos (Fig.
6E). We also analyzed primary MEFs isolated from the embryos,
and found that necroptosis induced by H2O2 or T+L+Z was
substantially reduced in the DKO MEFs compared with FADD
KO cells (Fig. S9). These results demonstrate that PUMA con-
tributes to necroptosis in vivo and in vitro caused by FADD
deficiency.
Discussion
Necroptosis and apoptosis share upstream pathways mediated by
cell surface death receptors and can be triggered by a variety of
stimuli that would normally induce apoptosis. On activation by
TNF-α, RIP1 binds to and activates RIP3, which in turn activates
MLKL by phosphorylation, leading to formation of a necrosome
complex. RIP1 not only functions as a kinase to promote nec-
roptosis, but also can act as a scaffold protein to inhibit nec-
roptosis (24). The execution of necroptosis involves translocation
of MLKL to the plasma and cytoplasmic membranes, where it
promotes cell death through unclear mechanisms (32). Our results
demonstrate that RIP3/MLKL-dependent PUMA induction pro-
motes signal amplification in TNF-driven necroptosis in diverse
cell types, such as epithelium, fibroblast, and developmental em-
bryos. Unlike RIP1 or RIP3 KO, which rescues postnatal death of
FADD KO mice (31), PUMA KO in mice partially rescues em-
bryonic development before birth and after E13.5, consistent with
its functional role in a rather late stage of necroptosis.
In addition to PUMA, several other Bcl-2 family members
have been implicated in necroptosis. Bmf, also a BH3-only
protein, was identified by a siRNA screen as being involved in
TNF-α–induced necroptosis (12). Prosurvival proteins, such as
Bcl-XL, inhibit TNF-induced necroptosis (13). Unlike apoptosis,
in which PUMA and other BH3-only proteins function through
Bax/Bak to kill cells, necroptosis clearly does not require Bax and
Bak (33), and can engage PUMA to kill BAX/BAK-deficient
MEF and cancer cells (Fig. S6 D and E).
The induction of PUMA in necroptosis is mediated by MLKL
through enhanced NF-κB activity and autocrine TNF-α signaling
(Fig. 2). On RIP1/RIP3-mediated activation, MLKL oligomerizes
and translocates to plasma and cytoplasmic membranes, where
it promotes membrane rupture and release of cellular contents,
including damage-associated molecular patterns (DAMPs) (34).
These and other MLKL-mediated changes in early necroptosis can
trigger inflammatory responses, which stimulate autocrine TNF-α
and PUMA induction, leading to signal amplification in a positive
feedback loop and eventual cell death (Fig. 6F). Autocrine TNF-α
can be induced in response to IAP antagonists or excessive DNA
damage (35), as well as in L929 cells undergoing necroptosis (36).
Fig. 6. PUMA deficiency rescues defective embryonic development and sup-
presses necroptosis in FADD KO embryos. (A) Representative pictures of mouse
embryos with indicated FADD and PUMA genotypes at 13.5 d (E13.5).
(B) Western blots of FADD and PUMA in E13.5 embryos with the indicated
genotypes. (C) Expected and observed numbers of embryos with the indicated
FADD and PUMA genotypes from 185 dissected E13.5 embryos. ***P < 0.001,
FADD−/−/PUMA−/− vs. FADD−/−/PUMA+/+; NS, P = 0.5252, FADD−/−/PUMA−/− vs.
the expected ratio of Mendelian inheritance (χ2 test). (D) HMGB1 staining of
fibroblast tissues from E13.5 embryos with the indicated genotypes. Arrow-
heads indicate cells with cytoplasmic HMGB1 staining and hollow nuclei. (Scale
bars: 10 μm.) (E) Western blots of indicated proteins in E13.5 embryos with the
indicated genotypes. (F) Model depicting the role of PUMA in necroptosis.
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NF-κB–mediated transcription was also found to be involved in
necroptosis induced by RIP3 oligomerization (37). However, add-
ing exogenous TNF-α can make necroptosis less dependent on NF-
κB–mediated transcription (Fig. 3D and Fig. S2E), likely related to
enhanced initial MLKL phosphorylation (38).
Necroptosis can be triggered by exogenous viral DNA or bac-
terial infection (26); however, whether necroptosis signaling in-
volves release of endogenous self-DNA is not quite clear. Our
results suggest that PUMA promotes changes in mitochondrial
morphology and cytosolic release of mitochondrial DNA to acti-
vate the DNA sensors DAI/Zbp1 and STING. PUMA was pre-
viously shown to promote mitochondrial fission (39), which can
lead to release of mitochondrial DNA (40). On release, mito-
chondrial DNA, which shares common ancestry and homology with
bacterial DNA, can act as an endogenous DAMP to activate innate
immunity (41). Activation of DAI/Zbp1 and STING collectively
promotes enhanced RIP3/MLKL phosphorylation (Fig. 6F). It is
likely that DAI/Zbp1 does so by directly recruiting RIP3 through its
RHIM domains (26). STING can be activated by cytosolic mito-
chondrial DNA (42) and mediate the IFN response in RIP3-de-
pendent necroptosis on viral infection (27). Our data suggest that
PUMA induces the STING-mediated IFN response to enhance
RIP3/MLKL phosphorylation; however, the role of mitochondria
in necroptosis is controversial and remains to be verified (43).
Collectively, our results demonstrate that RIP3/MLKL-dependent
PUMA induction promotes signal amplification and contributes to
the execution of TNF-driven necroptosis in vitro and in vivo.
Materials and Methods
Cell Culture and Drug Treatment. Cells were maintained in a 37 °C incubator at
5% CO2. Cell culture media were supplemented with 10% defined FBS
(HyClone), 100 U/mL penicillin, and 100 μg/mL streptomycin (Invitrogen).
Cells were plated and treated by drugs at 40–50% density in 12-well plates.
Analysis of Cell Viability and Death. Cell viability was analyzed by measuring
ATP levels and crystal violet staining. Apoptosis was measured by counting
cells with condensed and fragmented nuclei. Additional details are provided
in SI Materials and Methods.
Analysis of Protein and mRNA Expression. Western blot analysis and real-time
RT-PCR were performed as described previously (15).
Transfection and siRNA/shRNA Knockdown. Transfection of plasmids and siRNA
was performed using Lipofectamine 2000 (Invitrogen) in accordance with the
manufacturer’s instructions.
Analysis of Mitochondrial DNA, Proteins, and Membrane Potential. Mitochon-
drial and cytosolic fractions were isolated by differential centrifugation as
described previously (15). Additional details on mitochondrial analysis are
provided in SI Materials and Methods.
Analysis of Mouse Embryos. All animal experiments were approved by the
University of Pittsburgh’s Institutional Animal Care and Use Committee.
Additional details are in provided in SI Materials and Methods.
Statistical Analysis. Statistical analyses were performed using GraphPad
Prism 4.
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